Imiquimod

Approved Uses

Imiquimod cream is primarily used to treat the following conditions:

• Actinic keratosis: These are flat, scaly growths on the face or scalp caused by long-term sun exposure. The medication is used for adults with healthy immune systems to help clear these precancerous lesions.
• Superficial basal cell carcinoma: This is a type of skin cancer. Imiquimod is used when the cancer is located on the trunk, neck, or limbs, and when surgical treatment is not considered the most appropriate option.
• External genital and perianal warts: It is used to treat warts on the outside of the body in the genital and anal areas. This application is approved for adults and children aged 12 years and older.

Important Considerations

When used for genital warts, imiquimod treats the visible warts but does not cure the underlying virus (human papillomavirus or HPV). Because the virus may still be present in the body, new warts can develop during or after treatment. It also does not prevent the spread of warts to others through skin-to-skin or sexual contact.

This medication is intended for external use only. It is not used to treat warts located inside the vagina, penis, or rectum.

Mechanism of Action

Imiquimod is classified as an immune response modifier. Unlike many other topical treatments, it does not directly kill viruses or destroy cancer cells. Instead, it works by stimulating the body's own immune system to attack the skin condition being treated.

When the medication is applied to the skin, it triggers the production of natural substances called cytokines, such as interferon. These substances are part of the body's signaling system that helps regulate immune responses. By increasing these signals locally, imiquimod encourages the immune system to recognize and eliminate abnormal cells or the virus that causes certain types of warts.

The exact mechanism of how imiquimod works for all its approved uses is not completely understood. However, research indicates that it activates specific receptors in the immune system, which then leads to the destruction of targeted skin lesions.

Common Side Effects

• Redness, itching, or burning at the application site
• Flaking, scaling, or dryness of the skin
• Swelling, scabbing, or crusting
• Changes in skin color, which may be permanent
• Headache or dizziness
• Tiredness or muscle aches
• Diarrhea or back pain

Serious Side Effects

Seek medical attention immediately for any of the following:

• Severe skin reactions including blistering, bleeding, or deep sores (ulcers)
• Signs of infection such as pus or extreme warmth and swelling
• Severe flu-like symptoms, including high fever and chills
• Painful or difficult urination when used in the genital or anal area
• Swollen lymph nodes

Local skin reactions are common and often indicate that the medication is working to stimulate the immune system. If these reactions become too severe or interfere with daily activities, a healthcare provider may recommend a rest period from the medication.

Local Skin Reactions

Imiquimod often causes skin reactions at the site of application. Common responses include redness, swelling, scabbing, and skin peeling. If a severe skin reaction occurs, the medication should be washed off and a healthcare professional consulted. Treatment may need to be interrupted until the skin heals.

Sun Exposure

Exposure to sunlight and UV light from tanning beds or sunlamps should be avoided or minimized during treatment. Imiquimod can make the skin more susceptible to sunburn. Protective clothing and wide-brimmed hats are recommended when exposure cannot be avoided.

Systemic Symptoms

Flu-like signs and symptoms may occur during treatment. These can include fever, fatigue, nausea, and joint or muscle pain. If these symptoms develop, a healthcare provider should be notified to determine if treatment should continue.

Usage Restrictions

The cream should not be applied to areas of broken skin or open wounds until they have fully healed. It is intended for external use only and should not be used in the eyes, nose, or mouth. Additionally, imiquimod may weaken latex condoms and diaphragms, potentially leading to contraceptive failure.

Pregnancy

There are no adequate and well-controlled studies of imiquimod use in pregnant women. In animal studies where imiquimod was administered orally at high doses, some evidence of developmental toxicity was observed. However, the amount of medication absorbed through the skin in humans is generally much lower than the doses used in these animal studies. Because animal studies are not always predictive of human response, imiquimod should be used during pregnancy only if clearly needed and after consultation with a healthcare provider.

Breastfeeding

It is not known whether imiquimod is excreted in human milk following topical application. Because many drugs can be passed to an infant through breast milk, healthcare providers recommend exercising caution when using imiquimod cream while nursing. It is important to discuss the potential risks and benefits with a doctor before using this medication if you are breastfeeding.

Topical Cream

Imiquimod is available as a cream for application to the skin. It is commonly found in the following strengths:

• 2.5%
• 3.75%
• 5%

The medication is typically packaged in single-use packets or multi-dose pump bottles. Single-use packets are designed to be used once and then discarded, even if some cream remains. Pump bottles dispense a specific amount of medication with each use.

FDA Approval Status

Imiquimod was first approved by the U.S. Food and Drug Administration (FDA) in 1997. It is classified as an immune response modifier and is available by prescription only.

Approved Indications

The FDA has approved imiquimod for the treatment of the following conditions:

• Actinic Keratoses: Treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.
• Superficial Basal Cell Carcinoma: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults when surgical methods are less appropriate.
• External Genital and Perianal Warts: Treatment of external genital and perianal warts (condyloma acuminata) in patients 12 years of age and older.

Safety and Regulatory Oversight

There are currently no FDA boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with imiquimod. Regulatory approval is specific to the concentration of the cream and the specific condition being treated. It is not approved for use inside the vagina, anus, or urethra.

Uses and Application

Imiquimod cream is primarily prescribed for the treatment of actinic keratoses on the face or scalp, superficial basal cell carcinoma when surgery is not appropriate, and external genital or perianal warts. It works as an immune response modifier, helping the body recognize and fight specific skin issues.

The cream is applied directly to the affected area, typically before bedtime. The frequency of application varies based on the condition being treated:

• For actinic keratosis, it is usually applied twice a week for 16 weeks.
• For superficial basal cell carcinoma, it is typically applied five times a week for 6 weeks.
• For genital or perianal warts, it is often applied three times a week for up to 16 weeks.

Proper Use

It is important to wash the hands and the treatment area with mild soap and water before application. After applying a thin layer and rubbing it in until it vanishes, the area should be left uncovered; bandages or waterproof dressings should not be used. The cream should remain on the skin for the amount of time directed by a healthcare provider (usually 6 to 10 hours) before being washed off.

Imiquimod cream is for external use only and should not be used in the eyes, nose, mouth, or inside the vagina or anus. Because the medication can weaken condoms and diaphragms, alternative forms of protection or abstinence may be necessary during treatment for genital warts.

Storage and Handling

The cream is often supplied in single-use packets. Once a packet is opened, any remaining cream should be discarded and not saved for future use. If using a pump, follow specific priming instructions provided with the product. The medication should be stored at room temperature and kept away from heat or freezing temperatures.